Last reviewed · How we verify
NCT05573984
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
trial in Retinitis Pigmentosa in 50 participants. Participants enrolled and being followed up; not accepting new ones.
9 September 2026
Quick facts
| Lead sponsor | PYC Therapeutics |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 7 July 2022 |
| Primary completion | 9 September 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 7 locations across United States, Australia |
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
- Eye Diseases, Hereditary — all drugs for Eye Diseases, Hereditary →
- Retinal Dystrophies — all drugs for Retinal Dystrophies →
- Retinal Dystrophy Rod — all drugs for Retinal Dystrophy Rod →
Sponsor
PYC Therapeutics — full company profile →
Who can join
10 and older, any sex, with Retinitis Pigmentosa or Eye Diseases, Hereditary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05573984
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Other PYC Therapeutics trials
Trials by the same sponsor.
- NCT06970106 — Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) · Phase 1, PHASE2 · recruiting
- NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
- NCT06455826 — MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) · Phase 1 · completed
- NCT06140329 — Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation · terminated
- NCT05902962 — SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05573984 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PYC Therapeutics
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05573984.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing